Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours

被引:0
|
作者
Pedro Marques
Sayka Barry
Eivind Carlsen
David Collier
Amy Ronaldson
Sherine Awad
Neil Dorward
Joan Grieve
Nigel Mendoza
Samiul Muquit
Ashley B. Grossman
Frances Balkwill
Márta Korbonits
机构
[1] Queen Mary University of London,Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry
[2] STHF,Department of Pathology
[3] The National Hospital for Neurology and Neurosurgery,Department of Neurosurgery
[4] UCLH,Department of Neurosurgery
[5] NHS Trust,Barts Cancer Institute, Barts and the London School of Medicine and Dentistry
[6] Charing Cross Hospital,undefined
[7] Imperial College,undefined
[8] Derriford Hospital,undefined
[9] Queen Mary University of London,undefined
关键词
Pituitary neuroendocrine tumour; Pituitary adenoma; Tumour microenvironment; Cytokine; Chemokine; Immune cell; Macrophages; Lymphocytes; Neutrophils; Epithelial-to-mesenchymal transition;
D O I
暂无
中图分类号
学科分类号
摘要
Non-tumoural cells within the tumour microenvironment (TME) influence tumour proliferation, invasiveness and angiogenesis. Little is known about TME in pituitary neuroendocrine tumours (PitNETs). We aimed to characterise the role of TME in the aggressive behaviour of PitNETs, focusing on immune cells and cytokines. The cytokine secretome of 16 clinically non-functioning PitNETs (NF-PitNETs) and 8 somatotropinomas was assessed in primary culture using an immunoassay panel with 42 cytokines. This was correlated with macrophage (CD68, HLA-DR, CD163), T-lymphocyte (CD8, CD4, FOXP3), B-lymphocyte (CD20), neutrophil (neutrophil elastase) and endothelial cells (CD31) content, compared to normal pituitaries (NPs, n = 5). In vitro tumour–macrophage interactions were assessed by conditioned medium (CM) of GH3 (pituitary tumour) and RAW264.7 (macrophage) cell lines on morphology, migration/invasion, epithelial-to-mesenchymal transition and cytokine secretion. IL-8, CCL2, CCL3, CCL4, CXCL10, CCL22 and CXCL1 are the main PitNET-derived cytokines. PitNETs with increased macrophage and neutrophil content had higher IL-8, CCL2, CCL3, CCL4 and CXCL1 levels. CD8+ T-lymphocytes were associated to higher CCL2, CCL4 and VEGF-A levels. PitNETs had more macrophages than NPs (p < 0.001), with a 3-fold increased CD163:HLA-DR macrophage ratio. PitNETs contained more CD4+ T-lymphocytes (p = 0.005), but fewer neutrophils (p = 0.047) with a 2-fold decreased CD8:CD4 ratio. NF-PitNETs secreted more cytokines and had 9 times more neutrophils than somatotropinomas (p = 0.002). PitNETs with higher Ki-67 had more FOXP3+ T cells, as well as lower CD68:FOXP3, CD8:CD4 and CD8:FOXP3 ratios. PitNETs with “deleterious immune phenotype” (CD68hiCD4hiFOXP3hiCD20hi) had a Ki-67 ≥ 3%. CD163:HLA-DR macrophage ratio was positively correlated with microvessel density (p = 0.015) and area (p < 0.001). GH3 cell-CM increased macrophage chemotaxis, while macrophage-CM changed morphology, invasion, epithelial-to-mesenchymal transition and secreted cytokines of GH3 cells. PitNETs are characterised by increased CD163:HLA-DR macrophage and reduced CD8:CD4 and CD8:FOXP3 T cell ratios. PitNET-derived chemokines facilitate macrophage, neutrophil and T cell recruitment into the tumours which can determine aggressive behaviour.
引用
收藏
相关论文
共 50 条
  • [21] Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study
    Sabrina Chiloiro
    Pier Paolo Mattogno
    Flavia Angelini
    Antonella Giampietro
    Alessandra Vicari
    Greis Konini
    Federico Valeri
    Amato Infante
    Natalia Cappoli
    Rosalinda Calandrelli
    Liverana Lauretti
    Simona Gaudino
    Marco Gessi
    Guido Rindi
    Alessandro Olivi
    Laura De Marinis
    Antonio Bianchi
    Francesco Doglietto
    Alfredo Pontecorvi
    Pituitary, 2025, 28 (2)
  • [22] Biomaterials tools to modulate the tumour microenvironment in immunotherapy
    Yu Chao
    Zhuang Liu
    Nature Reviews Bioengineering, 2023, 1 (2): : 125 - 138
  • [23] NEUROENDOCRINE TUMOURS - MODELS FOR RARE TUMOUR MANAGEMENT
    Chan, David L.
    Goldstein, David
    Zalcberg, John R.
    CANCER FORUM, 2015, 39 (01) : 13 - 16
  • [24] PANCREATIC NEUROENDOCRINE TUMOURS - A RARE PANCREATIC TUMOUR
    Chan, David L.
    Pavlakis, Nick
    Roach, Paul
    Bailey, Dale
    Arena, Jennifer
    Segelov, Eva
    CANCER FORUM, 2016, 40 (01) : 34 - 39
  • [25] Genetics of neuroendocrine tumours, hereditary tumour syndromes
    Igaz Peter
    ORVOSI HETILAP, 2013, 154 (39) : 1541 - 1548
  • [26] Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours
    Meyer, Tim
    Caplin, Martyn
    Khan, Mohid S.
    Toumpanakis, Christos
    Shetty, Shishir
    Ramage, John K.
    Houchard, Aude
    Higgs, Kate
    Shah, Tahir
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (04)
  • [27] Systematic evaluation of the immune microenvironment of neuroendocrine tumours (NET)
    Vesely, C.
    Childs, A.
    Wong, Y. N. S.
    Ogunbiyi, O.
    Luong, T. V.
    Thirlwell, C.
    Caplin, M.
    Marafioti, T.
    Quezada, S.
    Meyer, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Fractionated radiotherapy to temporally modulate the tumour microenvironment for immunotherapy
    Ebert, M.
    Keam, S.
    D'Alonzo, R.
    Gill, S.
    Nowak, A.
    Cook, A.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S690 - S691
  • [29] The concurrent occurrence of neuroendocrine tumour and gastrointestinal stromal tumours
    Rathod, Divya
    Shukla, Samarth
    Acharya, Sourya
    Vagha, Sunita
    JOURNAL OF KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITY, 2022, 11 (04) : 92 - 96
  • [30] Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience
    Mihajlovic, Milena
    Pekic, Sandra
    Doknic, Mirjana
    Stojanovic, Marko
    Rasic, Dejan
    Miljic, Dragana
    Petakov, Milan
    Manojlovic Gacic, Emilija
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2024, 32 (03) : 470 - 477